• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ocular Therapeutix closes enrollment in Phase II study of tear duct plug

June 4, 2013 By drugdelivery

OcularTherapeutix

Ocular Therapeutix wrapped up patient enrollment for a Phase II trial evaluating the company’s OTX-DP tear duct plug, the company announced this week.

The study included 60 patients recovering from corneal cataract surgery. Patients were divided into 2 treatment groups – one was treated with anti-inflammatory steroids delivered by Ocular’s plug and the other was given a placebo plug with optional rescue medication in case of persistent inflammation, a company spokesperson told MassDevice.com.

Each patient was observed over a 2-week period with the tear duct plug in place, and Ocular expects it will have all patient results in July.

The Bedford, Mass.-based company developed its drug-eluting plug with help of a series of funding rounds and is currently pursing an investigational new drug submission with the FDA.

Ocular developed the drug/device combo as an alternative to delivering post-surgery medication via patient-administered eye drops. The plug, inserted in the tear duct, automatically delivers drugs to the surface of the eye.

"A sustained, low-dose dexamethasone plug could ensure consistent and continuous corticosteroid concentrations on the ocular surface, which may in turn minimize side effects and achieve better results," said CEO Amar Sawhney in prepared remarks.

In January the company closed a nearly $24 million Series D extension round that Sawhney told MassDevice.com he intended to use to develop the plug technology.

Filed Under: Drug-Device Combinations Tagged With: Clinical Trials, Ocular Therapeutix Inc

IN CASE YOU MISSED IT

  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS